Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Dual Ligand-Enabled Palladium Catalysis: Unlocking Novel Reactivities and Selectivities in Aromatic C–H Activation (DULICAT)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Synthetic Chemistry and Materials
Panel description: New materials and new synthetic approaches, structure-properties relations, solid state chemistry, molecular architecture, organic chemistry
Countries involved: Germany,Germany
Call: ERC STARTING GRANTS (ERC-2020-STG, 2020)
Start date: 2021-08-01
End date: 2026-07-31
Duration (months): 60.0
Total project cost (EUR): 1872500.0
EU funding (EUR): 1660657.5
Participants: 2
Project status: SIGNED

The transition metal catalyzed activation of aromatic carbon-hydrogen (C–H) bonds has enabled a variety of novel transformations that complement traditional approaches towards complex aromatic compounds. The vast majority of methods developed in this field relies on the use of directing groups, which coordinate the catalyst prior to the C–H activation step to induce activity and selectivity. In contrast, nondirected methods have remained underdeveloped, since it has remained highly challenging to achieve reactivity and induce good selectivities in such processes. My research group has recently discovered a new design paradigm for palladium catalysts, which exhibit extraordinary activities and selectivities. Through the combined action of two complementary ligands these catalysts enable the activation of arenes without requiring a directing group or the use of an excess of the substrate. Here, I propose to initiate a broadly conceived research project aiming at three major goals: 1) The development of highly active palladium catalysts that can activate even the most challenging arene substrates. This goal will be pursued by building a broad ligand library and conducting systematic structure activity studies that are designed to deliver an in-depth mechanistic understanding. 2) The development of catalysts that enable high sterically controlled regioselectivities. This goal will be tackled using a mechanism-based design approach, aiming to minimize the influence of electronic effects and to suppress unintended directing effects. 3) The development of novel synthetic methods for late-stage functionalization. A particular focus will be on transformations that exhibit otherwise challenging regioselectivities and deliver attractive motifs for medicinal chemistry. Overall this project is expected to establish dual ligand-enabled palladium catalysis as a novel tool in synthetic organic chemistry that will prove highly useful in both academic and industrial laboratories.

Keywords: palladium catalysis,c h activation,late stage modification
Computed tomography targets for efficient guidance of catheter ablation in ventricular tachycardia (MAP-IN-HEART)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: France
Call: ERC Proof of Concept Grant (ERC-2019-PoC, 2019)
Start date: 2020-12-01
End date: 2022-08-31
Duration (months): 21.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 2
Project status: CLOSED

Patients at risk of ventricular tachycardia (VT), the primary cause of sudden cardiac death, commonly undergo catheter ablation to cauterize the areas within myocardial scars responsible for arrythmias. However, the initial phase of the intervention devoted to identifying the ablation targets currently involves the intra-cardiac insertion of a mapping catheter characterized for being invasive, often inaccurate, and time-consuming. Pre-operative implementation of 3D cardiac imaging approaches to provide detailed structural information on ablation targets could overcome the shortcomings of standard catheter-based mapping. Still, state-of-the-art techniques have not lived up to their potential so far. During his ERC Starting Grant ECSTATIC (2017-2022), Prof. Hubert Cochet at University of Bordeaux developed a novel 3D image-processing technology (MAP-IN-HEART) which would allow cardiologists to locate VT ablation targets and guide ablation procedures in a non-invasive, highly precise and rapid manner using widely available cardiac CT images, without the need for a mapping catheter. In this ERC PoC project, we will investigate the technical feasibility of the innovative MAP-IN-HEART approach by assessing its efficiency and safety in a limited clinical study, and performing a cost-efficiency analysis. Moreover, we will ensure Freedom-To-Operate and explore all the potential paths for commercialization to finally develop a viable business strategy based on the technological aspects, the market needs and trends. Lastly, during this project we will gain technical and commercial proof-of-concept, providing the necessary information for potential commercialisation routes.

Keywords: cardiovacular diseases,ventricular tachycardia,computed tomography,catheter ablation,cardiac 3d image
Transnational Access Programme for a Pan-European Network of HPC Research Infrastructures and Laboratories for scientific computing (HPC-EUROPA3)

Framework: Horizon 2020 — Excellent Science
Programme: Research Infrastructures
Theme: Research infrastructures
Destination: Integrating activities and infrastructures
Action type: Research and Innovation actions
Countries involved: Germany,Ireland,Spain,Italy,Finland,Sweden,Greece,France,Netherlands,United Kingdom
Call: Integrating Activities for Advanced Communities (H2020-INFRAIA-2016-1, 2016)
Start date: 2017-05-01
End date: 2022-04-30
Duration (months): 60.0
Total project cost (EUR): 9206161.5
EU funding (EUR): 9206161.5
Participants: 10
Project status: CLOSED

HPC-Europa3 aims at maintaining the persistency of a high quality service of transnational access to the most advanced HPC infrastructures available in Europe for the European research science community. European researchers could rely on the existence of such transnational access activity for almost two decades, and the main aim of this new innovative 3rd edition of HPC-Europa series is to fill the gap left in the four years since the end of the last initiative has ended. HPC-E3 also represents a powerful vector to enlarge the HPC PRACE users base by supporting the researchers in their early-career in HPC and numerical simulation, and by covering, with a specific and dedicated attention, two regions that still present potential of improvement: the Baltic and the Western Balkans regions. Objectives of HPCE3 will be: · Provide access to 8 European HPC centres (with a target of 1.220 visits), via a single application and an international peer-review process, free of charge and with minimal administrative overhead; · Mentor in the usage of the most advanced HPC facilities; · Facilitate new scientific collaboration to be formed within an extremely wide network of scientific host labs in all the computational sciences domains; · Increase awareness of the benefits in the use of HPC towards SMEs; · Increase synergy and collaboration with other HPC initiatives; · Identify a long-term sustainability roadmap to facilitate future access to HPC resources. The project is based on a program of visit, in the form of traditional transnational access, with researchers visiting HPC centres and/or scientific hosts who will mentor them scientifically and technically for the best exploitation of the HPC resources in their research. The visitors will be funded for travel, accommodation and subsistence, and provided with an amount of computing time suitable for the approved project. Two NAs and one JRA will maximize the effectiveness of the access service.

Keywords: transnational access,high performance computing,numerical simulations,regional support,trans disciplinarity,scientific collaboration visits,researchers mentoring,access to hpc research
Decreasing Pancreatic Adenocarcinoma-related Inflammation using small molecule inhibitors of STING (DIM-CrIC)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Immunity, Infection and Immunotherapy
Panel description: The immune system, related disorders and their mechanisms, biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases, innovative immunological tools and approaches, including therapies
Countries involved: France,France
Call: ERC Proof of Concept Grant (ERC-2019-PoC, 2019)
Start date: 2020-06-01
End date: 2021-11-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 2
Project status: CLOSED

We will develop and test a treatment for pancreatic ductal adenocarcinoma (PDAC). To this aim, we will synthesize and evaluate the efficacy of novel inhibitors of nucleic acid-induced inflammation that we have identified. Indeed, nucleic acid-induced chronic inflammation is a major driver of tumorigenesis. Because the canonical pathway that triggers nucleic acid-induced chronic inflammation relies on the STING protein, identifying ways to activate or inhibit STING is a major goal of current research. We have identified a novel endogenous pathway that antagonizes STING though the production of a second messenger molecule. This pathway prevents spurious STING activation and regulates nucleic acid-associated inflammation. We have developed a set of analogues of this small molecules for wich we demonstrate the ability to prevent STING activation in vitro and now wish to ameliorate the intracellular delivery of these molecules to assess their in vivo efficacy on PDAC-associated inflammation. PDAC is a suitable model for establishing the proof of concept of efficacy of the treatment we propose, because we show that knocking-out STING impairs PDAC growth. Therefore, DIM-CriC will provide novel means to tackle STING-dependent inflammation in PDAC. Ultimately, this work should pave the way to assessment in additional tumorigenesis models that present a STING-dependent inflammatory profile, unraveling a novel route to block cancer-related inflammation to the benefit of patients.

Keywords: sting,inhibitors,pancreatic adenocarcinoma,inflammation,cancer
Near-zero-index nanophotonic technologies (NZINATECH)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Systems and communication engineering
Panel description: Electrical, electronic, communication, optical and systems engineering
Countries involved: Spain
Call: ERC STARTING GRANTS (ERC-2020-STG, 2020)
Start date: 2021-01-01
End date: 2025-12-31
Duration (months): 60.0
Total project cost (EUR): 1499625.0
EU funding (EUR): 1499625.0
Participants: 1
Project status: SIGNED

Near-zero-index (NZI) media is a family of photonic nanostructures (continuous media and/or metamaterials) characterized by a near-zero refractive index. As the refractive index approaches zero, spatial and temporal variations of the electromagnetic field decouple, giving rise of a regime of qualitatively different light-matter interactions. Therefore, NZI nanostructures exhibit a unique optical response, where a concept as basic as the geometry plays an essentially different role. Examples of the exotic wave phenomena include transmission through deformed waveguides, cavities whose resonant frequency does not depend on the geometry of their external boundary, nonradiating modes in three-dimensional open cavities, violation of effective medium theories, anomalous dispersion, nonperturbative nonlinear optics, to name a few. These unconventional effects have a high potential for technological innovation. However, the crucial challenge of transforming these basic phenomena into practical devices has not yet been addressed. In NZINATECH, we will address this challenge pushing forward the basic theoretical research on NZI media to the stage of NZI nanophotonic technologies. To this end, we have outlined an ambitious research plan that includes the experimental demonstration of NZI devices in different material platforms, including polar dielectrics, doped semiconductors and silicon photonics. This multidisciplinary research plan will combine the fields of NZI media, metamaterials, quantum optics, electron-beam spectroscopy, thermal emission and silicon photonics. Our results will also open new areas of research for NZI media, including nontrivial interactions of NZI optical modes with free-electrons and small quantum systems. Finally, by examining fundamental questions in limiting cases (i.e., extreme constitutive parameters) we will provide a better understanding of the quantum theory of light-matter interactions.

Keywords: near zero index media,metamaterials,nanophotonics
Innovative 5-part haematology analyser for near-patient diagnostics (INNOHEM)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Sweden
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-1-2015, 2015)
Start date: 2015-12-01
End date: 2016-05-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The INNOHEM project will develop and validate the first Complete Blood cell Count (CBC) haematology analyser including 5-part differential and reticulocytes (5-part analyser) for the decentralized, low-volume testing haematology market. Today, CBC tests are performed using either 3-part or 5-part analysers. The latter are growing in importance worldwide as they are able to provide much more detailed information about the medical condition of the patient. However, 5-part analysers are currently designed entirely for the high-volume testing market with complex, centralized laboratories equipped with large sample automation devices. Recognising market niche and a strong business opportunity, Boule will create a revolutionary point-of-care analyser that will provide reliable 5-part haematology results from a finger-stick blood sample. The new system will disrupt the existing marketplace by redefining the segment for the commercial application of 5-part analysers (from high-volume centralized testing to low-volume near-patient testing). The key need of physicians is the access to an easy-to-deploy analyser for 5-part CBC testing. The analyser should be designed for easy operation in smaller laboratory settings. The users’ needs will be met by creating a user-friendly diagnostic device that allows for low-volume, decentralized and near-patient testing. The Phase 1 project will develop a strategic business plan for the commercialisation of the new product. The Phase 2 project will validate the new diagnostic device. The EU added value will be generated by allowing physicians to make a rapid health assessment of the patient locally and take improved decisions concerning further diagnostic measures or immediate treatment strategy. This will ultimately lead to more personalized and cost-efficient approaches to healthcare on the EU level.

Keywords: haematology analysers,decentralized haematology market,point of care haematology diagnostics
Worldwide Interoperability for SEmantics IoT (Wise-IoT)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Research and Innovation actions
Countries involved: Spain,Germany,Spain,Switzerland,France,France,France,United Kingdom,United Kingdom
Call: IoT joint research (H2020-EUK-2016-1, 2016)
Start date: 2016-06-01
End date: 2018-05-31
Duration (months): 24.0
Total project cost (EUR): 1776810.75
EU funding (EUR): 1499895.75
Participants: 11
Project status: CLOSED

While the Internet of Things is addressing a multiplicity of still-emerging standards and Alliance specifications with efforts to structure them into reference architectures, the Wise-IoT project gathers lead contributors from Europe and Korea to on-going major global IoT standardisation activities with the objective to strengthen and expand emerging IoT standards and reference implementation using feedback from user-centric and context-aware pilots. Based on morphing mediation gateways concept, a trust-based recommendation system is proposed, leveraging upon Context Information APIs enabling end-to-end semantic interoperability and the dynamic distribution of analytic functions over a proposed ‘Global IoT Services’ (GIoTS). These GIoTS provide IoT virtualisation and interaction with systems beyond IoT together with trust building and management capabilities. Six testbeds from Europe and South Korea will be federated to implement smart city, leisure and healthcare pilots demonstrating GIoTS based applications roaming capabilities across continents. An iterative development approach is being implemented to allow requirement and architecture adjustments as well as alignment and contributions back to on-going standardisation activities through submissions in technical committees and interoperability events support. A strong plan for dissemination has been set-up and will have its peak during the trials to be run at PyeongChang Olympic and Paralympic Games. The consortium composed of prestigious research institutes, SMEs and large industries from Europe and Korea and will work in tandem to contribute to the success of the Wise-IoT project. Wise-IoT will give a particular attention to create an environment encouraging European and Korean SMEs and startups to enter the IoT industry by enabling access to a unified platform where interoperability among heterogeneous data in smart environments will be provided.

Keywords: data,standardisation,pilot,architecture
FAST-BM: FibroSelect: delivering A Step-change in Biotherapeutic Manufacturing (FAST-BM)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Biotechnology
Action type: SME instrument
Countries involved: United Kingdom
Call: Dedicated support to biotechnology SMEs closing the gap from lab to market (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-08-01
End date: 2016-12-31
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Seven of the top 10 global medicines by spending are biotherapeutics drugs, and the market is growing at a CAGR of 10.1% to reach a value of $287 billion in 2020. Challenges facing biotherapeutic manufacture are: i) Chromatographic purification, accounting for >50% of processing costs. This is important given the increasing price sensitivity of payers worldwide and serves as a limitation to the growth of the biosimilar industry; ii) Increasing diversity and complexity of biotherapeutics: ~70% of biopharma’s product pipeline are large complex proteins (e.g. bispecific antibodies, fusion proteins or viral vectors), which offer promising therapeutic opportunities, but cannot be manufactured cost effectively as they do not fit with current bioprocessing platform technologies; iii) Process flexibility: The rapidly evolving industry is moving to more flexible disposable formats to cope with uncertainty in drug development and varying market demand. Puridify has developed an innovative bioprocessing platform technology, FibroSelect, a functionalised cellulose chromatography medium to enable high-productivity, product capture and purification that is economic to operate in a disposable manner. FibroSelect addresses each point above by i) enabling cost reductions of up to 25% (potentially £700K - £2.7m per batch); ii) offering flexibility to design new bioprocessing platforms; iii) being a wholly disposable system where all purifying ligand is expended per-batch purification. It is innovation in the latter area that helps to drive costs down and increase productivity, as the requirement for cleaning columns and re-validating prior to purification of the next batch of biotherapeutic product is ameliorated. FibroSelect eases process constraints and enables flexibility through single-use processing opportunities thereby maximising facility utilisation as has been seen with the rapid growth in use of single-use technologies for manufacturing.

Keywords: biotherapeutic manufacture,biologics,bioprocessing,biomolecules,purification
Energy-efficient and high-bandwidth neuromorphic nanophotonic Chips for Artificial Intelligence systems (ChipAI)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Research and Innovation actions
Countries involved: Spain,Switzerland,Netherlands,United Kingdom,Portugal,United Kingdom,Portugal
Call: FET-Open Challenging Current Thinking (H2020-FETOPEN-2018-2019-2020-01, 2018)
Start date: 2019-03-01
End date: 2022-11-30
Duration (months): 45.0
Total project cost (EUR): 3892005.0
EU funding (EUR): 3892005.0
Participants: 9
Project status: SIGNED

The same way the internet revolutionized our society, the rise of Artificial Intelligence (AI) that can learn without the need of explicit instructions is transforming our life. AI uses brain inspired neural network algorithms powered by computers. However, these central processing units (CPU) are extremely energy inefficient at implementing these tasks. This represents a major bottleneck for energy efficient, scalable and portable AI systems. Reducing the energy consumption of the massively dense interconnects in existing CPUs needed to emulate complex brain functions is a major challenge. ChipAI aims at developing a nanoscale photonics-enabled technology capable of deliver compact, high-bandwidth and energy efficiency CPUs using optically interconnected spiking neuron-like sources and detectors. ChipAI will pursue its main goal through the exploitation of Resonant Tunnelling (RT) semiconductor nanostructures embedded in sub-wavelength metal cavities, with dimensions 100 times smaller over conventional devices, for efficient light confinement, emission and detection. Key elements developed are non-linear RT nanoscale lasers, LEDs, detectors, and synaptic optical links on silicon substrates to make an economically viable technology. This platform will be able to fire and detect neuron-like light-spiking (pulsed) signals at rates 1 billion times faster than biological neurons (>10 GHz per spike rates) and requiring ultralow energy (<10 fJ). This radically new architecture will be tested for spike-encoding information processing towards validation for use in artificial neural networks. This will enable the development of real-time and offline portable AI and neuromorphic (brain-like) CPUs. In perspective, ChipAI will not only lay the foundations of the new field of neuromorphic optical computing, as will enable new non-AI functional applications in biosensing, imaging and many other fields where masses of cheap miniaturized pulsed sources and detectors are needed.

Keywords: semiconductor nanostructures,quantum resonant tunnelling,nanoscale sub wavelength lasers,leds and detectors,metal cavities,optical interconnects,neuromorphic photonics,spiking neural networks